Armata Pharmaceuticals reports Q2 EPS (25c) vs. (17c) last year

Reports Q2 grant revenue $0 vs. $980,000 last year. As of June 30 Armata held approximately $26.4M of unrestricted cash and cash equivalents, as compared to $13.5M as of December 31, 2023. “During the Q2 and subsequent period, we made meaningful progress across both of our clinical programs, keeping us on track to potentially initiate pivotal studies next year,” stated Deborah Birx, CEO of Armata. “Regarding AP-PA02, which we are developing as an inhaled treatment for chronic P. aeruginosa lung infections, I am pleased to report that we recently completed enrollment and the last patient visit in our Phase 2 Tailwind study in subjects with NCFB, and we plan to announce topline data later this year.”